Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study ...Middle East

LUND, Sweden, Oct. 17, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced results from an extended pooled analysis using data from the 17-HMedIdeS-14 study,1 an international long-term...

Hence then, the article about imlifidase demonstrated 90 patient survival and 82 graft survival at five years in extended pooled analysis with data from 17 hmedides 14 study was published today ( Tuesday 17/10/2023 - 08:40 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study )

Also on site :

• William Shatner, 95, Walked Onstage With a Band Nobody Expected Him to Front; the ‘Star Trek’ Legend Covered Ozzy Osbourne and Metallica in Chicago
• Convera and JustLogin Partner to Enable Cross-Border Payroll and Payments Across Singapore and Southeast Asia
• Trump Gets Caught in a Dilemma Over a Saudi Plea for Military Help